Tomeglovir
CAS: 233254-24-5
Ref. 3D-IJA25424
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
- Bay-38-4766
- N-[4-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)phenyl]-3-hydroxy-2,2-dimethylpropanamide
Tomeglovir is a monoclonal antibody that has been designed to target the enzyme non-nucleoside polymerase. This drug is an oral prodrug that has been developed for the treatment of hepatitis B and C, as well as herpes simplex virus and influenza virus. Tomeglovir inhibits the RNA-dependent DNA polymerase of these viruses, which prevents them from replicating in cells. Tomeglovir also binds to human T-cell leukemia virus type 1 (HTLV-1) and blocks its reverse transcriptase, inhibiting viral replication. Tomeglovir is in phase II clinical trials for cancer and hepatitis C.